CPHI
MILAN
2026

INVITATION

Meet Taiwan's Pharmaceutical Delegation

Taiwan–Italy Pharmaceutical Business Matching Meeting

7 October 2026 | 13:30–17:00

Aquarius Meeting Room, Fiera Milano

Pre-scheduled one-to-one meetings with 22 Taiwanese pharmaceutical and biotechnology companies

Taiwan Pharma Pavilion

Booth 8F2

CONTACT Elijah Huang | Project Manager | Taiwan Bio Industry Organization | elijah@taiwanbio.org.tw

A 22-company delegation built for practical partnerships

Five capability clusters cover the pharmaceutical value chain from discovery to commercialization.

22

participating companies

5	4	6	3	4
Innovative Medicines	Value-added Medicines	API / CDMO	Complex Generics	CRO / AI services

One delegation. Multiple entry points for product, technology, manufacturing and market partnerships.

Five clear pathways to work with Taiwan

The figures show how many delegation companies have indicated interest in each cooperation model.

4	**API Supply**	APIs, intermediates and specialty chemical supply
11	**CDMO / CMO Services**	Small molecules, biologics and finished dosage forms
17	**Licensing / Co-development**	Products, pipelines and platform technologies
9	**Technology Transfer**	Process, formulation and manufacturing know-how
11	**Distribution / Agent Partnerships**	European registration, commercialization and market access

All 22 companies and their partnership interests

Select the companies or cooperation areas most relevant to your business.

API = API supply · LIC = licensing / co-development · TT = technology transfer · DIST = distributor / agent · FDF = finished dosage form

COMPANY	PARTNERSHIP INTEREST
TaiMed Biologics	CDMO · LIC
PhytoHealth	LIC
InnoPharma	API · LIC · DIST
OP NanoPharma	CDMO · LIC
Yung Zip Chemical	API · CDMO · DIST
Yung Shin Pharma	API · CDMO · LIC · TT
Mithra Biotechnology	Analytical support
ITRI-AIDD	LIC
PeiLi Pharmaceutical	CDMO · LIC · TT · DIST
Taho Pharma	LIC · DIST
Sciwin Laboratories	API · CDMO · TT

COMPANY	PARTNERSHIP INTEREST
Adimmune	CDMO · LIC · TT · DIST
Anxo Pharmaceutical	CDMO · LIC · TT · DIST
Vernus AI	AI solutions
Gilva Therapeutics	CDMO · LIC / out-lic.
Seven Star Pharma	CDMO · DIST · FDF
CytoArm	LIC · TT · DIST
TLC BioSciences	LIC · DIST
Precisemab Biotech	LIC · TT
GlycoNex	CDMO · LIC · TT · DIST
TSH Biopharm Group	LIC · TT · DIST
Repurgenesis	LIC

Meet the 22 Taiwan Pharma Delegation Companies at the Pavillion

TAIWAN PHARMA PAVILION

Hall 8 · Stand 8F2

Contract Manufacturing & Services zone

Booth concept · guest-facing view

Plan your visit: Matching session on 7 October at Aquarius Meeting Room

BUSINESS MATCHING · 7 OCTOBER

Aquarius Meeting Room



Upper Floor · Stella Polare Congress Centre



Pre-arranged 20-minute one-to-one meetings.

Detailed access guidance will be shared with confirmed participants.

Flexible 20-minute meetings built around confirmed interest

7 OCTOBER 2026

13:30–17:00

Aquarius Meeting Room
Fiera Milano

20 minutes

per one-to-one meeting

The number of meeting rounds will be adjusted according to confirmed participants and mutual matches.

- **13:30** Registration and networking refreshments
- **14:00** Opening remarks and delegation introduction
- **14:40** **Pre-scheduled one-to-one meetings begin**
- **15:40** Networking break / schedule buffer
- **16:00** **Additional meetings or open networking**
- **16:40** Extended discussions and networking

Tentative agenda — exact meeting rounds and break timing will be finalized after confirmations.

Choose the partners you want to meet

We will build a meeting schedule around mutual interests.

1

Review

Browse the company profiles

2

Select

Indicate companies or cooperation areas

3

Submit

Complete the interest form

4

Meet

Receive a confirmed 1:1 schedule

CONTACT

Elijah Huang | Project Manager

Taiwan Bio Industry Organization

elijah@taiwanbio.org.tw

Taiwan Pharma Pavilion | Booth 8F2

Submit by 25 August 2026 for priority scheduling.

Open the interest form →

COMPANY PROFILES

Meet the 22 companies behind the delegation

Products, platforms, manufacturing capabilities and partnership interests

Profiles are provided for business-matching purposes.

TaiMed Biologics Inc.

TaiMed Biologics 中裕新藥

- ## Core Products / Technologies
  - CD4-targeted antibody assets from clinical to commercial stage
  - contract development and manufacturing services (CDMO) for monoclonal antibodies
- ## Manufacturing & Development Capabilities :
  - our CDMO services spanning process development, analytical method development, formulation and clinical to commercial-scale production.
- ## Regulatory & Compliance Status:
  - TaiMed Biologics HsinChu facility has undergone two independent on-site inspections by the U.S. FDA in 2022 and 2023.
- ## Target Partners / Target Markets：
  - TaiMed is seeking global development and commercialization partners for TMB-365/380
  - Seeking pharmaceutical, biotech, and emerging life-science companies looking for reliable outsourced drug development and manufacturing partners.
- ## One-sentence Company Highlight：
  - TaiMed Biologics is a biopharmaceutical company leveraging its CD4-targeting platform to develop innovative antibody therapeutics and provide biologics development and manufacturing capabilities.

PhytoHealth https://www.phytohealth.com.tw/en

PhytoHealth

- PG2 Lyo. Injection (Rx) : cancer-related fatigue treatment
  Oraphine Soft Capsules (Rx): relieve moderate to severe acute pain
  Dietary Supplements
- Manufacturing & Development Capabilities : R&D and formulation development
- Regulatory & Compliance Status: PIC/S GMP, **DMF and GACP**
- **Target Partners / Target Markets：Product License-in and -out**
- **One-sentence Company Highlight：**

PhytoHealth Corporation is an innovative biopharmaceutical company recognized for developing PG2®, Taiwan's first approved botanical prescription drug, and Oraphine®, the world's first oral nalbuphine formulation.

INNOPHARMAX

www.innopharmax.com

- **Core Products / Technologies**
  - D07001 GemOral (oral Gemcitabine softgel capsule)
  - BendaReady (bendamustine RTD injection)
  - OralPAS oral drug delivery platform
- **Manufacturing & Development Capabilities**
  - R&D/formulation development
  - Pilot scale/ scale-up
  - Marketed products support
- **Regulatory & Compliance Status**
  - DMF: 3 active/inactive, and 1 ASMF in registration
  - Export experience: EU, ASEAN
- **Target Partners / Target Markets**
  - Global / Regional
  - Partners seeking to in-license and/or co-develop 505(b)(2)assets
  - Distribution partners for API and FDF
  - Partners seeking to develop products using INNOPHARMAX's core drug delivery platforms
- **One-sentence Company Highlight**

InnoPharmax is a clinical-stage pharmaceutical company (TPEx: 4172) focused on development and commercialization of oral new dosage form products, utilizing proprietary drug delivery technology platforms such as OralPAS®

OP NanoPharma Co., Ltd.
友杏生技醫藥股份有限公司

Sterile Injectable CDMO | Licensing Opportunities

US FDA Inspected Facility | PIC/S GMP

- Core Products / Technologies
  - Sterile Injectable CDMO HPAPI & ADC Products Solution & Lyophilized Vials
- Manufacturing & Development Capabilities
  - Formulation Development Tech Transfer Clinical to Commercial Manufacturing CMC Support
- Regulatory & Compliance Status
  - US FDA Inspected, PIC/S GMP, Global Development Experience
- Target Partners / Target Markets
  - European Pharma, Biotech Companies, Licensing Partners, CDMO Collaboration
- One-sentence Company Highlight
  - End-to-end sterile injectable solutions from formulation development to commercial manufacturing, with licensing opportunities for innovative injectable products.

OEP Group Website

友杏生技
OP NanoPharma

Your Trusted Partner for Sterile Injectable Development, Manufacturing & Licensing

US FDA Inspected Facility | PIC/S GMP Compliant

1 Core Expertise

- Sterile Injectable CDMO
- HPAPI & ADC Products
- Solution & Lyophilized Vials

Focus on high value injectable products

2 Capabilities

- Formulation Development
- Process Development & Tech Transfer
- Analytical & CMC Support
- Clinical Supply
- Commercial Manufacturing

End-to-end support from development to commercialization

3 Licensing Opportunities

Ready-to-Partner Injectable Pipeline

- **Lacosamide Injection 200 mg**
  Treatment for partial-onset seizures
- **Carfilzomib Lyophilized Injection 10 mg / 30 mg / 60 mg**
  Treatment for relapsed or refractory multiple myeloma

Additional pipeline available upon request

4 Regulatory & Compliance

- US FDA Inspected Facility
- PIC/S GMP Compliant
- GMP for Clinical & Commercial Manufacturing
- Global Regulatory Support

Proven track record supporting global development programs (US, EU, Asia)

5 Target Partners / Target Markets

- Pharmaceutical Companies
- Biotech Companies
- Licensing / Co-development Partners
- Companies Seeking Sterile Injectable CDMO
- Companies Developing HPAPI or ADC Products

We look forward to connecting with partners who share our commitment to bringing innovative medicines to patients worldwide.

6 One-Sentence Company Highlight

Delivering innovative sterile injectable solutions—from formulation development to commercial manufacturing, and licensing opportunities for high-value therapies worldwide.

15+ CDMO Projects | **IND / NDA** Submission Support | **Clinical to Commercial** Manufacturing | **HPAPI & ADC** Expertise | **Global Experience** US, EU, Asia

YUNG ZIP CHEMICAL

A world-class cGMP API manufacturer and specialty chemical solution provider with over 30 years of proven US FDA compliance and advanced particle engineering expertise.

Regulatory & Compliance (The Foundation of Trust)

10+ **Consecutive US FDA Audits Passed**

30+ **Proven cGMP Compliance History**

Global Filings Matrix

- ☑ US DMF
- ☑ CEP (EU)
- ☑ KDMF (KR)
- ☑ PMDA (JP)

Immediate LOA support for seamless IND/NDA submissions.

Core Products & Capabilities (The Engine)

cGMP APIs

Precision Particle Size Distribution (PSD) tuning (D10 / D50 / D90).

Polymorph & Crystal customization for superior bioavailability & defensible IP.

Specialty Fine Chemicals

Electronic & semiconductor grade purity (ppb-level trace metal control).

Agile Manufacturing Flow

28-Day
Agile R&D sample delivery & synthetic route screening.

Seamless Scale-Up
Flexible transition from 1kg pilot to multi-ton commercial cGMP supply.

Advanced Synthesis
Expertise in high-hazard reactions, organometallics, and continuous flow chemistry.

Target Partners & Markets (The Destination)

505(b)(2) Co-Developers

Seeking partners working on complex dosage forms like ODF, patches, and injectables who need custom crystal/polymorph screening to bypass originator patents.

Global Pharma & CDMOs

Seeking highly reliable, FDA-cleared API supply chain continuity out of Taiwan.

Specialty Chemical Innovators

Targeting users in electronics, high-purity reagents, and agrochemicals requiring strict impurity profiling.

Yung Shin Pharmaceutical Industrial Co., Ltd. (YSP)

Your Trusted Global Partner in Quality, Innovation, and Pharmaceutical Excellence

Founded in 1952, YSP specializes in high-quality pharmaceutical products and offers end-to-end CDMO/CMO services. With a strong GMP system and the compliance with US FDA, PMDA, TGA, & Health Canada, YSP is committed to delivery the best products to improve human health.

2 API Manufacturing Platforms

15+ Dosage Forms

20+ Production Lines

35 Exporting Countries

70+ Years Pharmaceutical Excellence

Regulatory Compliance: FDA • PMDA • TGA • Health Canada

Integrated Quality System: eQMS • LIMS • Empower • APS

R&D

- Strain Engineering & Optimization
- Synthetic Route & Peptide Development
- Process & Formulation Optimization
- Scale-up & Technology Transfer

Unique Technology

- Liposomal Formulations
- Microspheres
- Sustained-release Systems
- Nanoparticle Delivery

GMP Manufacturing

- **API:** Fermentation & Chemical Synthesis
- **Drug Product:** Injectable • Oral • Topical
- Sterile & High Potence (Antibiotic & Oncology) Process Handling

Partnering Offerings

- Licensing (Product/Technology)
- Co-Development
- Contract Services (CDMO/CMO)

Mithra Biotechnology Inc.

https://www.mithracro.com/

- Integrated Biosimilar Development Solution– from Analytical Similarity to PK Comparability
- OECD GLP Laboratory, USFDA GMP-inspected
- Target Partners/Markets:
  - ✓ Biologics & Biosimilar Developers
  - ✓ CDMOs seeking analytical and bioanalytical partners
  - ✓ Pharmaceutical companies outsourcing specialized CRO services



-- Integrated Analytical Solutions Across the Biosimilar Development Journey --

工業技術研究院
Industrial Technology Research Institute

Expert-Led Precision Drug Development Platform: SEAL & CTag

ITRI integrates disease-target intelligence, AI-driven molecular design, ADMET & PK prediction, virtual screening, and retrosynthesis to accelerate precision drug discovery from target identification to lead generation.

SEAL: Target Discovery & Drug Repurposing

- Disease–target–drug knowledge integration
- Target prioritization & drug repurposing
- 50M+ biomedical relationships
- Novel indication and target discovery

CTag: AI-Driven Drug Design Platform

- AI molecular generation
- ADMET & PK prediction
- Virtual screening & docking
- Experimental validation and model refinement

Target Partners

- Pharma & biotech companies
- Hospitals & academic institutes
- Drug discovery companies & CROs
- Licensing & co-development partners

Development Capabilities

- Target discovery & validation
- Hit generation & optimization



Technology Highlight

SEAL finds the right target; CTag designs the right molecule. We support an integrated drug discovery pipeline.

Since 1976

PEI LI PHARMACEUTICAL INDUSTRIAL CO., LTD.

培力藥品 PeiLi Pharm

Location

Taichung (Taiwan):

Headquarters and Manufacturing Site.

PIC/S GMP Certification

Japan PMDA GMP Compliance Approval

Product Focus

- Hormonal tablets & formulations
- Control-released drugs
- Non-cytotoxic oncology drugs
- Soft capsules
- Women's health supplements
- Suppositories
- Generic small molecule portfolio

Our Capabilities

Dedicated High Potency Production Units (Hormonal tablets)
Soft Capsules Production Units
Generic small molecule portfolio: Tablets (ODT, CRT), Capsules, Suppositories, Ointment

Comprehensive R&D unit

Regulatory affairs expertise

Technology Transfer

CDMO / CMO

License In & Out

Scan for more info

- **One-sentence Company Highlight**：Taiwan's pioneer in hormone manufacturing, Pei Li Pharmaceutical specializes in high-potency pharmaceuticals and provides internationally certified CMO/CDMO solutions for global partners.

TAHO Pharma

https://www.tahopharma.com/en/

- **Core Products / Technologies:**

  Core Products : Apixaban ODF and extended-release ODF technologies for 505(b)(2) cardiovascular products

  505(b)(2):

TAH3311 – Apixaban ODF for dysphagia patients; EU MA filing in progress
TAH3341 – ER version of Apixaban ODF
TAH0031 – Nintedanib buccal film for antifibrotic treatment
TAH2231 – Naloxone buccal film for opioid overdose emergency treatment

  Generic:

TAH4411 – Ondansetron oral dissolving film approved and marketed in Japan
TAH9901 – Methylphenidate transdermal patch for ADHD
TAH9922 – Atomoxetine oral solution for pediatric ADHD and swallowing-difficulty patients

- **Manufacturing & Development Capabilities :** R&D/ API reformulation development
- **Regulatory & Compliance Status:** Phase I GMP
- **Target Partners / Target Markets**：Licensing out/Co-development, Distributor/ Agent partnership
- **One-sentence Company Highlight**：TAHO Pharma is a Taiwan-based specialty pharmaceutical company transforming patient care through innovative oral, buccal, and transdermal drug delivery technologies.
- **Technologies:** API formulation integration and controlled-release drug delivery development capabilities

SCIWIN Laboratories Co., Ltd.

click for more info

1. Core Capabilities

Specializing in Organic Synthesis, Process Development, and Custom Manufacturing for Biopharmaceutical and Semiconductor Industries.

- ADC-Novel linker-Payloads
- Organic synthesis-Small molecule & macromolecule
- Process Development & Optimization
- Custom synthesis-reference & impurity standard.

2. Service Scope (End-to-End CDMO)

- R&D ➔ Process Optimization ➔ Tech Transfer ➔ GMP Manufacturing.

3. Team Track Record

- 10+ years in ADC-linker/high potent API
- 15+ years of GMP manufacturing
- >500 projects completed

4. Target Markets & Partners

- Biotech & Novel Drug Developers | API & Pharma Manufacturers | CDMO Partners

We offer professional process optimization services and assist in transferring products to GMP facilities for GMP-grade manufacturing, we are committed to providing our clients with the highest quality service.

- **Core Products / Technologies**
  Adimmune Group's core products and technologies cover a wide range, including human vaccines, animal vaccines, and medical diagnostic tools. In the field of human vaccines, currently marketed products include EnVAX-A71(Enterovirus A71 Vaccine), AdimFlu-S (Influenza vaccine) , and a tetanus vaccine. Adimmune utilizes five distinct technology platforms to maintain international-level vaccine development.
- **Manufacturing & Development Capabilities**
  CMO & CDMO Solutions for Vaccines and Biologics
  Manufacturing Platforms about Embryonated Egg-Based Vaccines, Cell Culture-Based Vaccines, Recombinant Protein Vaccines, Pre-Filled Syringes (PFS) and Vial Fill & Finish
- **Regulatory & Compliance Status**
  Adimmune is recognized or certified by major health agencies, including: U.S. FDA , EMA , Canada , Brazilian , Taiwan , Thailand.
- **Target Partners / Target Markets**
  EU US Pharmaceutical companies looking for CDMO partners
- **One-sentence Company Highlight**
  Adimmune Group A global vaccine leader with 5 technology platforms, 9 international certifications (FDA/EMA), and PIC/S GMP manufacturing excellence

Anxo Pharmaceutical Co., Ltd.

www.anxo.com.tw

- **Core Products / Technologies**
  - *Solid Dispersion in Oil-Phase Technology*: Isotretinoin, Nintedanib Soft capsule
  - *Osmotic-controlled Release Oral Delivery System:* Methylphenidate, Paliperidone, Nifedipine, Doxazosin ER Tablet

- **Manufacturing & Development Capabilities** :
  - CMO and CDMO of complex generic products
  - Technical Transfer for local manufacturing

- **Regulatory & Compliance Status:**
  - PIC/S GMP facilities commercial supply US, MENA, Japan, China, Korea, and ASEAN markets.

- **Target Partners / Target Markets**
  - Pharmaceutical companies seeking licensing-in opportunities
  - Commercial partners for exclusive distribution
  - Companies seeking technology transfer or co-development
  - Generic pharmaceutical companies expanding specialty portfolios

- **One-sentence Company Highlight：**
  - Your trusted partner for complex generics, advanced drug delivery technologies, and successful global commercialization.

Vernus AI (https://vernus.ai/)

- Core Products / Technologies

SMALL MOLECULES · PROCESS R&D

ReAIX Chem

v1.1 · Production

AI co-pilot for CMC chemists — searches, optimizes and de-risks reactions with quantum-accelerated reasoning.

BIOLOGICS · ANTIBODY ENGINEERING

ReAIX Bio

v1.0 · Production



From sequence to scale-up — AI-driven antibody design, developability prediction and bioreactor optimization.

FORMULATION · DRUG PRODUCT

ReAIX Formulation

v1.0 · Production

De-risk formulation decisions. Predict API–excipient compatibility, stability, dissolution and PK before the bench.

- Vernus ReAIX agents provide AI solutions for drug manufacturing optimization purpose by utilizing **AI**, **Quantum Computing** and **Physical Simulation**.
- **Target Partners / Target Markets**：Vernus expect to reach out and collaborate with pharmaceutical and CDMO companies around the world. The collaboration can be AI platform licensing or project collaboration.
- **One-sentence Company Highlight**：Vernus is your best partner in transforming pharmaceutical manufacturing, and we look forward to collaborations with you!

Gilva Therapeutics

https://gilvatherap.com

Innovating HDAC6 Therapeutics for Unmet Medical Needs

Gilva Therapeutics is a clinical-stage biopharmaceutical company focused on the discovery and development of small molecule drugs for diseases with high unmet medical need. Leveraging a robust drug discovery platform based on structure-activity relationship (SAR) and an experienced team, we developed first-in-class and best-in-class therapeutic candidates with enhanced efficacy, safety, and druggability. GV-100 Phase I clinical trial is ongoing in Australia, and Phase II drug product is being manufactured under GMP.

Core Products / Technologies

GV-100
Selective HDAC6 inhibitor for ADPKD and fibrotic diseases

Why HDAC6?

- Regulates multiple cellular pathways via post-translational modifications
- Implicated in the pathogenesis of ADPKD, fibrotic diseases, neurodegenerative disorders and cancers
- Represents a potential target for disease-modifying therapy

Target Indication: ADPKD

ADPKD is an inherited disorder characterized by progressive kidney cyst growth and loss of renal function.

- About 85% of cases caused by PKD1 mutation
- PKD1 variants are generally associated with more severe disease
- Current therapy (Tolvaptan) dose not address epithelial proliferation and has potential liver toxicity risk



GV-100 aims to provide a safer and more effective disease-modifying therapy.

Manufacturing & Development Capabilities

- **Drug Discovery**
  Proprietary SAR-driven platform supported by an experienced multidisciplinary team.
- **Formulation and CMC development**
  Preformulation, formulation development, and CMC strategy.
- **Clinical supply manufacturing through qualified CDMO partners**
  Pilot scale, scale-up, and GMP clinical through qualified CDMO partners.

Regulatory & Compliance Status

- **GMP**
  Clinical drug substance and drug product are manufactured in accordance with GMP.
- **Compendial-Grade Excipients**
  USP/NF-grade excipients
- **Clinical Supply Distribution**
  Experience in international shipping and global regulatory support.
- **Regulatory Strategy**
  ICH-compliant CMC development strategy for global regulator submissions.

Target Partners

- Licensing and Co-development Partners
- Regional commercialization Partners
- Strategic Investors
- Regulatory Partner

Target Markets

- USA
- Europe
- Greater China
- Japan

Seven Star Pharmaceutical Co., Ltd.

- **Core Products / Technologies**
  Acetylcysteine, Methocarbamol, Gadopentetate Dimeglumine, Gadoterate Meglumine, Gadobutrol Monohydrate, Sapropterin Dihydrochloride, Guaifenesin , Carbocisteine

- **Manufacturing & Development Capabilities : R&D/formulation development、Pilot scale/ scale-up、Commercial manufacturing.....**
  API Manufacturing and Development, from R&D, pilot scale, to commercial manufacturing.

- **Regulatory & Compliance Status: GMP 、DMF 、Export experience.....**
  PIC/S GMP, with multiple products registered worldwide including US, EU, China, and so on.
  Full export experience in North and Latin America, EU, Asia, and Africa market.

- **Target Partners / Target Markets：**
  CDMO / CMO service 、 Distributor / Agent partnership Finish Dosage Manufacturer

- **One-sentence Company Highlight：**
  A leading API manufacturer holding PIC/S GMP, with multiple APIs approved by USFDA, EU, and China authorities.
  Our products are exported among North and Latin America, EU, Asia, and Africa market.

Advancing Next-Generation Armed T-Cell Therapies

Executive Summary

- **CytoArm** is a clinical-stage biotechnology company developing its proprietary Armed-T platform to address cancers and autoimmune diseases with significant unmet medical needs.
- This cutting-edge technique and advances in process construct design have the following benefits:

  - ✓ **Virus-Free**
  - ✓ **Rapid Manufacturing (10 days)**
  - ✓ **High Purity (>90% Armed-T purity)**
  - ✓ **High Safety (low cytokine storm)**
  - ✓ **High Efficacy (multi-dose treatment)**
  - ✓ **Low Cost**

- The company has built a broad global IP portfolio covering more than 50 product candidates, supported by a leading international patent law firm.

Partnering Opportunity

CytoArm seeks global and regional partners for licensing, novel-target and allogeneic co-development, commercialization, and strategic investment.

Lead Program: CTA-002

- CTA-002 is an EGFR-targeting Armed-T therapy for advanced colorectal cancer, with expansion potential in pancreatic, lung, triple-negative breast, and head and neck cancers.
- Industrial process development and multiple simulation / clinical batches have been completed.
- A compassionate-use program in Taiwan is providing preliminary human feasibility, pharmacodynamic, and safety observations.
- Preparations for international Phase I/IIa studies are underway.

Armed-T Product Pipeline



1st Armed-T Product [CTA-002] for "EGFR-Overexpressing Solid Tumors"

- Taiwan: Compassionate-use treatment ongoing in colorectal cancer patients.
- Taiwan, U.S., Singapore & China: IND preparation for Phase I/IIa clinical trials.

https://cytoarm.com/

- Core Products / Technologies



- TLC conducts in-house R&D/formulation development and collaborates with international CROs for clinical trials and CMOs for commercial manufacturing of its Phase 3 programs.

- Seeking partners to out-license our Phase 3 programs in pain management – TLC599 (6 months of OA pain relief with 1 injection) and TLC590 (168 hours of postsurgical pain relief with 1 dose).

Precisemab Biotech Co., Ltd.

Precisemab 碩準生技股份有限公司 Biotech Co., Ltd.

https://precisemab.com/

Core Products / Technologies

Universal Antibody Lock Platform

PrecisemAb develops a conditionally activated antibody platform designed to keep therapeutic antibodies functionally masked in healthy tissues and selectively reactivate them in disease microenvironments through disease-associated proteases.

The platform is applicable to:

- Monoclonal antibodies
- Antibody-drug conjugates, Lock-ADCs
- Bispecific antibodies
- Oncology and immune-mediated disease targets



Manufacturing & Development Capabilities :

PrecisemAb provides integrated antibody engineering and preclinical development capabilities, including:

- Antibody Lock design and molecular engineering
- CDX, PDX, orthotopic and humanized mouse models
- Preliminary formulation, developability and CMC assessment

Pilot-scale production, process development, scale-up and GMP manufacturing can be conducted in collaboration with qualified external CDMO partners.

Target Partners / Target Markets：

- Global and regional pharmaceutical companies
- Biotechnology companies developing antibodies, ADCs or bispecific antibodies
- Licensing, co-development and feasibility-study partners

One-sentence Company Highlight：

PrecisemAb transforms conventional antibodies into conditionally activated therapeutics that remain masked in healthy tissues and selectively unlock at disease sites, enabling safer and more effective antibody medicines.

GlycoNex: Anti-Glycan Antibody & Biosimilar Development

GlycoNex Inc.

Why GlycoNex: GlycoNex combines glyco-science, antibody engineering, biologics development, and clinical-stage execution to build differentiated antibody therapeutics and biosimilar assets.

Anti-Glycan Antibody Platform

- Tumor-associated glycan targeting
- Anti-glycan ADC in Phase 1
- For antibody & ADC licensing or co-development

Biosimilar Development

- Integrated biosimilar development platform
- Denosumab biosimilar Phase 3 completed
- For regional licensing, supply, and commercialization

Development Capabilities

- R&D and formulation development
- Process scale-up and manufacturing
- Analytical comparability

Target Partners

- Pharma companies
- Licensing and co-development partners
- Regional distributors and commercial partners

Company Highlight

Advancing anti-glycan innovation and biosimilar development from discovery to clinical and commercial partnerships.



- **Core Products / Technologies**

Fixed-dose combination antihypertensive tablet

A Taiwan-developed FDC product with proven commercialization, export and international registration experience.

- **Manufacturing & Development Capabilities :**

Taiwan-based commercial manufacturing and quality control
FDC tablet formulation, registration dossier support and market launch experience
Export development experience for selected international markets

- **Regulatory & Compliance Status:**

Manufactured and marketed in Taiwan; exported to Thailand and Malaysia
Marketing authorization obtained in Myanmar
Clinical / BE data available upon request

- **Target Partners / Target Markets：**

Distribution partners, licensing collaborators and local registration partners
International market development beyond Southeast Asia
Partners seeking established cardiovascular products

- **One-sentence Company Highlight：** TSH Biopharm is a Taiwan-based specialty pharmaceutical company with experience in product development, commercial manufacturing, regulatory registration, and international market deployment of value-added medicines.

Repurgenesis https://repurgenesis.com

Core Products / Technologies

- Intelligent Orchestrator — proprietary AI-driven drug repurposing platform
- New-indication IP portfolio for patent-licensing collaboration

Manufacturing & Development Capabilities

AI-driven drug repurposing R&D — new-indication discovery and IP development

Regulatory & Compliance Status:

- Export experience: ☑ US ☑ EU ☑ Japan

Target Partners / Target Markets：

We are primarily seeking biotechnology and pharmaceutical partners interested in drug repurposing programs, new indication development, and early-stage candidate assets, with potential opportunities for out-licensing, co-development, and strategic R&D collaboration.

One-sentence Company Highlight：

Repurgenesis leverages its proprietary Intelligent Orchestrator platform to identify, prioritize, and advance new indications for existing drugs toward early validation, intellectual property development, and licensing .